Extended Data Fig. 5: anti-TIGIT treatment modulation of tumour infiltrating immune cells and peripheral blood monocytes depends on the Fc region.
From: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
a, UMAP of single cells from tumour infiltrating T and NK cells (top, n = 21,407) and myeloid cells (bottom, n = 5,352) coloured by cell types. b, Bubble plots showing marker gene expression for T and NK cells (left) and myeloid cells (right) as shown in (a).c-e, Heatmaps showing the expression of selected genes across different treatments in tumour macrophages and monocytes combined (c), tumour CD8 + T cells combined (d), and tumour CD4+ Tregs (e). f, UMAP of single cells from the peripheral blood (n = 26,174) coloured by cell types. g, Bubble plots showing the marker gene expression of cell types as in (f). h, Heatmap displaying the scaled gene expression of marker genes distinguishing classical, non-classical, and intermediate monocytes, and the expression patterns of FcɣR. i, Heatmap showing the scaled gene expression of MHC and interferon response in non-classical monocytes across different treatments. a-i, Single cell RNA-seq was performed on intratumoural (a-e) and peripheral (f-i) CD45+ cells isolated at day 3 after treatment, and data are from one independent experiment with n = 5 mice in each group.